Emergent BioSolutions Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Biologics License Application (sBLA), allowing its Winnipeg, Canada facility to serve as the drug product manufacturing and testing site for raxibacumab, a monoclonal antibody used for the treatment and prevention of inhalational anthrax. This regulatory approval supports Emergent's ongoing transformation strategy by strengthening its manufacturing network and consolidating operations in Winnipeg, Canada and Lansing, Michigan.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9601369-en) on December 12, 2025, and is solely responsible for the information contained therein.